Saved AI-generated translation. Medicine names, original references and image labels stay in their original language. The USA or UK edition stays the same.Traducción guardada generada por IA. Los nombres de medicamentos, las referencias originales y las etiquetas de las imágenes conservan su idioma original. Se mantiene la edición de EE. UU. o del Reino Unido.
La versión en español ya está guardada en este sitio. Al elegir Español no se envía el artículo a un servicio de traducción.
Hallucinogen-Related Disorders
Hallucinogen-related problems include acute distress, harmful use and persistent changes in perception. UK assessment distinguishes the actual substance and symptoms rather than treating all psychedelics and dissociatives as identical.
Hallucinogen-related disorders is a family overview, not the name of one uniform disease. It includes clinically significant problems associated with substances that alter perception, thinking or awareness. Classic psychedelics such as LSD and psilocybin differ from dissociative substances such as PCP, and classification systems do not group every substance identically.
Intoxication, a sustained use disorder, substance-induced psychiatric symptoms and persisting perceptual symptoms must be distinguished. An unusual experience, cultural practice or participation in legitimate research does not by itself establish a disorder.
Symptoms
Perception of time, surroundings and sensations can change markedly. Anxiety, panic, suspiciousness or confusion may occur. Some people report recurring or continuing visual disturbance afterwards. Symptoms and duration vary, so a substance name alone does not predict the experience.
Assessment
Assessment considers which products were taken, when symptoms began, other medicines or substances, sleep and mental health history. Persistent symptoms require evaluation of neurological, eye and psychiatric alternatives; diagnosisDiagnosisA clinical conclusion about the condition that best explains a person’s symptoms and other findings.Read the full definition of Diagnosis should not rest solely on a reported past exposure.
There is no single prevalence figure for this entire family. Studies may count lifetime exposure, recent use, a use disorder, emergency presentations or persisting perceptual symptoms, and these outcomes should not be conflated. Patterns also differ between classic psychedelics and dissociative substances.
Clinical trials usually involve selected participants and structured supervision, so their adverse-event rates do not describe every community exposure. Uncertainty about frequency does not make an individual's distress less real. The most useful evaluation focuses on the specific symptom pattern and its effects on daily life.
What Causes It?
Risk depends on the substance, product contents, setting, other substances and individual vulnerability. A history of certain psychiatric conditions may make exposure particularly concerning, and sleep loss or distress can complicate a reaction. Some substances can support compulsive patterns of use; others more often present through acute or perceptual complications.
Broad statements that all hallucinogens are nonaddictive or that everyone who uses them develops addiction are inaccurate. The reason symptoms persist in a particular person may remain uncertain, requiring careful follow-up rather than a confident single-cause explanation.
What Do We Know About the Brain?
These substances can alter brain processes involved in perception, emotional salience and the sense of self, but they do not all work in the same way. Classic psychedelics and dissociatives should therefore not be presented as one identical biological mechanism.
Research into therapeutic effects is still developing and cannot establish that an unsupervised experience is a treatment. Persistent perceptual symptoms are not diagnosed by a routine brain scan. Scientific uncertainty should be explained honestly without portraying distress as imaginary or assuming permanent damage from every exposure.
Conditions With Similar Symptoms
Migraine, seizure-related phenomena, eye disorders, anxiety, dissociationDissociationA change in the usual sense of connection with oneself, one’s body or the surroundings.Read the full definition of Dissociation and primary psychotic conditions can resemble some reported effects. Delirium and medical toxicity are important considerations when attention or consciousness is impaired. The timing of symptoms helps, but a history of hallucinogen exposure does not exclude another cause.
Clinicians distinguish recurrent visual disturbances with retained awareness from a broader loss of contact with reality, while recognising that presentations can overlap. Collapse or severe confusion requires emergency help immediately. Other persistent perceptual symptoms without emergency warning signs need medical assessment rather than an assumption of a harmless flashback.
Other Conditions That Can Occur Together
Anxiety, depression and other substance use may coexist with hallucinogen-related problems. Substance-induced psychosisPsychosisPsychosis describes symptoms that affect a person’s ability to tell what is real. These can include hallucinations, delusions and disorganised thinking or speech.Psychosis can occur with different mental or physical health conditions, some medicines or substance use. It does not automatically mean schizophrenia. New symptoms need prompt professional assessment. must be differentiated from an independent psychotic disorder, and persistent symptoms warrant follow-up. People may also experience trauma or distress related to a frightening event during intoxication.
Coexisting problems should be assessed individually rather than attributed to a stereotype about drug use. A person can need psychological support without having a use disorder, and someone with a use disorder may need additional medical treatment for a separate complication.
Treatment and support
Acute care prioritises medical safety and a calm environment. Continuing problems can be discussed with a GP or drug service, with specialist mental health or neurological input when needed. NHS drug services can develop an individual support plan rather than treating all exposures alike.
Medicines and evidence limits
No routine UK medicine regimen for HPPD is asserted here. FRANK explicitly notes limited understanding of susceptibility and treatment. Medicines for a diagnosed coexisting illness require an individual review; research into psychedelic therapy is not permission to self-treat with an unregulated product.
What to Expect Over Time
Many acute effects resolve as the exposure ends, but some people experience continuing anxiety, perceptual symptoms or other difficulties. Persistent problems deserve care even when tests are unrevealing. The course depends on the substance, complications and coexisting conditions, so no fixed recovery timetable is reliable for everyone.
Follow-up can clarify diagnosis and support a return to everyday activities. Avoiding further exposure may be part of a clinical plan, while additional substance use or self-medication can complicate assessment. Recovery should not be judged by stereotypes or sensational accounts.
Practical safety
Avoid driving or risky activities while judgement or perception is altered. With mushrooms, misidentification can cause poisoning unrelated to the intended psychedelic effect. Seek medical help for suspected poisoning rather than waiting to see whether it resembles a familiar experience.
When to seek urgent help
Immediate danger, collapse, seizure, severe confusion or suspected toxic mushroom ingestion warrants emergency help. Tell responders what may have been taken and when. Do not assume an intense reaction is harmless because a substance has been described as natural or non-addictive.
History
Some psychoactive plants and fungi have longstanding cultural and ceremonial histories, which should not be reduced to psychiatric pathology. Modern research and recreational exposure introduced different substances and settings, while classifications gradually distinguished their effects. Older discussions often treated hallucinogens as one class or assumed that an absence of a familiar physical withdrawalWithdrawalSymptoms that may occur after reducing or stopping a medicine or substance to which the body has adapted.Read the full definition of Withdrawal syndrome meant no possibility of harmful use.
Current frameworks are more specific. DSM and ICD separate substance groups and recognise several kinds of associated clinical problems. Renewed research into supervised psychedelic treatment is also distinct from unrestricted self-treatment: findings in selected study participants cannot automatically be applied to different products, settings or health histories outside research and regulated care.
World Health Organization · Updated 2024-03-08 · Accessed 2026-10-17
Article Information
Edition
United Kingdom
Content updated
2026-10-17
Sources checked
Listed with each reference above; retained dates for shared scientific content.
Publication status
Published
Scope
UK educational overview; specialist guidance may cover additional details.
Source and coverage limits
Shared DSM and ICD discussion explains international concepts; it does not claim that ICD-11 is uniformly implemented in NHS coding.
Named local NHS services and NICE recommendations do not establish identical commissioning or referral routes throughout the four UK nations.
Existing shared-science source dates are retained; newly checked UK references have their own actual access date.
Evidence for specific treatment of persistent perceptual symptoms remains limited; no unverified off-label medicine protocol or UK psychedelic licensing claim is added.